NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Kailera Therapeutics KLRA

Kailera Therapeutics listed on Nasdaq on 17 Apr 2026 and is not in the S&P 500. It is worth $1.5 billion. Its price history starts on 17 Apr 2026. 8 directors have filed with the SEC in the last 12 months (who counts), 1 of them an executive. 8 other officers are on file. At 30 Jun 2026, Bain Capital Investors was its largest institutional holder, with 20.3% of the company.

CEO
Ronald C. Renaud Jr.
Listed
17 Apr 2026 on Nasdaq, IPO filings and terms
Headquarters
Waltham, MA
Market cap
$1.5B
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Kailera Therapeutics' market cap since April 2026

Weekly, up to 13 Nov 2026

May 2026JunJulAugSepOctNov$1.7B

Board and leadership

Board and officers

2 people here also hold roles at other S&P 500 companies.

Roles filed up to 30 Sep 2026

NameTitle
Directors (8)
Ronald C. Renaud Jr.CEO & PresidentCEO & President
Frank ClyburnDirectorAlso at CencoraDirector
Christopher HiteDirectorDirector
Andrew T. KaplanDirectorDirector
Adam KoppelDirectorDirector
Yuting LiuDirectorDirector
Martin MackayDirectorAlso at Charles River LaboratoriesDirector
John F. MilliganDirectorDirector
Officers (8)
Douglas W. PaganChief Financial OfficerLast filed 20 Apr 2026Chief Financial Officer
Scott AkamineChief Legal OfficerLast filed 20 Apr 2026Chief Legal Officer
Paul D. BurgessChief Operating Officer & Chief Business OfficerLast filed 20 Apr 2026Chief Operating Officer & Chief Business Officer
Paula CloghessyChief People OfficerLast filed 20 Apr 2026Chief People Officer
Jamie Beth ColemanChief Commercial OfficerLast filed 20 Apr 2026Chief Commercial Officer
Nur NicholsonChief Technology OfficerLast filed 9 Sep 2026Chief Technology Officer
Kathleen TregoningChief Corporate Affairs OfficerLast filed 8 Jul 2026Chief Corporate Affairs Officer
Scott M. WassermanChief Medical OfficerLast filed 20 Apr 2026Chief Medical Officer

Owners and trading

Largest institutional holders

Each fund group's share of Kailera Therapeutics. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

These five hold 55.6% of Kailera Therapeutics.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers made no open-market sales and bought $159 million in 2 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
20 Apr 2026BuyAndrew T. KaplanDirectorDirectorBuy8,398,438$134M
20 Apr 2026BuyAdam KoppelDirectorDirectorBuy1,562,500$25M

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months, no quarterly results in its SEC XBRL filings and no director or officer changes, WARN notices or large insider sales in the last two years.